From Nobel to next-gen: Sweden’s quiet life sciences ascent
Sweden’s place on the frontier of science has a long history, with the capital Stockholm coming to a standstill every …
Post
-
-
Bavarian Nordic’s shareholders and board in standoff amid takeover offer
Bavarian Nordic’s board of directors has urged shareholders to accept a sweetened takeover offer as the potential sale of the …
-
Tubulis closes $361m in Series C to advance cancer treatment
Tubulis has completed a Series C financing round, securing €308m ($361m) that will primarily be directed towards advancing clinical development …
-
Oceanpine Capital to acquire 80% equity stake in Beijing Jacoray
Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for a total consideration of 200m …
-
Healthcare burden of neurological conditions “growing”, WHO warns
A new report from the World Health Organization (WHO) has highlighted the global healthcare burden of neurological disorders. In the latest …
-
Kirkland & Ellis dominates M&A legal advisory in first three quarters of 2025
Kirkland & Ellis has secured the foremost position as a legal adviser in the mergers and acquisitions (M&A) sector in …
-
Goldman Sachs and Houlihan Lokey lead in M&A advisory for Q1-Q3 2025
Goldman Sachs has secured the top spot as the leading financial adviser in mergers and acquisitions (M&A) based on deal …
-
Pfizer touts Tukysa in front-line breast cancer after Phase III victory
Pfizer’s Tukysa (tucatinib) has enhanced patient outcomes when used as a maintenance therapy during a late-stage trial in breast cancer. The …
-
Nabla Bio expands Takeda collab for protein therapeutics
Nabla Bio has entered a new multi-year research collaboration with Takeda to advance the AI-driven design of protein therapeutics. Nabla Bio …
-
BioCryst to buy Astria Therapeutics for $700m in enterprise value
BioCryst Pharmaceuticals has signed a definitive agreement to buy Astria Therapeutics with a mix of cash and stock transactions. The …
-
J&J spins off orthopaedics business against positive Q3 backdrop
Johnson & Johnson (J&J) has made the latest slimming down move across its company in recent years, saying it plans …
-
Kailera nets $600m to power Phase III launch of obesity drug
Just a year after emerging from stealth with a nearly half a billion dollars, Kailera Therapeutics has reached another financing …
-
China’s drugs offer lifeline for global pharma as it peers over the patent cliff
Out-licensing of clinical candidates from China has increased dramatically over the last five years, as the world’s pharma companies shore …
-
FDA approves AbbVie’s Rinvoq for inflammatory bowel disease
The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication statement for Rinvoq …
-
From strategy to submission: How your CRO should create value beyond execution
Biopharma innovators are operating in an environment shaped by the medical need for new and advanced therapies, the sheer volume …
